Cargando…

Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications

Detalles Bibliográficos
Autores principales:	Garcia, Gabriela E., Truong, Luan D., Johnson, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier, Inc., on behalf of the International Society of Nephrology. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404374/ https://www.ncbi.nlm.nih.gov/pubmed/34474076 http://dx.doi.org/10.1016/j.kint.2021.08.016

Ejemplares similares

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010)

Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2010)

Renin Angiotensin Converting Enzyme 2 and COVID-19: Prevention and Treatment
por: Kafami, Marzieh, et al.
Publicado: (2021)

COVID-19 and angiotensin-converting enzyme inhibitors from plant origin
por: Gharebaghi, Reza, et al.
Publicado: (2022)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Rossato, Marco, et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
por: Gupta, Nitesh, et al.
Publicado: (2020)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Determinants of circulating angiotensin-converting enzyme 2 protein levels in the general population
por: Kuznetsova, Tatiana, et al.
Publicado: (2021)

Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link
por: Van den Eynde, Jef, et al.
Publicado: (2021)

Another perspective for COVID-19 pandemic: Angiotensin-converting enzyme 2 and ethnicity
por: Simsek, Feride Irem, et al.
Publicado: (2020)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
por: Liu, Xiao, et al.
Publicado: (2020)

Angiotensin Converting Enzyme 2, Angiotensin-(1-7), and Receptor Mas Axis in the Kidney
por: Pinheiro, Sergio Veloso Brant, et al.
Publicado: (2012)

Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema
por: Kovaltchouk, Uliana, et al.
Publicado: (2021)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock
por: Pode-Shakked, Naomi, et al.
Publicado: (2023)

Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease
por: Wysocki, Jan, et al.
Publicado: (2008)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
por: Bombardini, Tonino, et al.
Publicado: (2020)

An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China
por: Wang, Jin, et al.
Publicado: (2022)

Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases
por: Motamed, Mohammad Reza, et al.
Publicado: (2015)

Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage
por: Joob, Beuy, et al.
Publicado: (2019)

Angiotensin‐converting enzyme gene variants interact with the renin–angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy
por: Cheema, Balneek Singh, et al.
Publicado: (2013)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019
por: Suh, Sang Heon, et al.
Publicado: (2021)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms
por: McLachlan, Craig Steven
Publicado: (2020)

What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?
por: John, Thadathilankal-Jess, et al.
Publicado: (2020)

Decreased Plasma Levels of Angiotensin-Converting Enzyme Among Patients With Bipolar Disorder
por: Sanches, Marsal, et al.
Publicado: (2021)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19
por: Vofo, Gaelle, et al.
Publicado: (2020)

Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19
por: Dabaghian, Farid, et al.
Publicado: (2020)

Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
por: Tsiambas, Evangelos, et al.
Publicado: (2020)

Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury
por: Vergara, Ander, et al.
Publicado: (2022)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System
por: Wysocki, Jan, et al.
Publicado: (2019)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
por: Cahova, Monika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_msa611rqvc7mibbqg8vvs0at81